However, in the PLATO trial the interaction was highly significant, unlike the ticagrelor-ASA interaction.
← all excerpts
Challenging the FDA black box warning for high aspirin dose with ticagrelor in patients with diabetes.
1
—
—
However, in the PLATO trial the interaction was highly significant, unlike the ticagrelor-ASA interaction.